Corcept Therapeutics Investor Relations Material
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders. The company offers Korlym tablets for use as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance, and who have failed surgery or are not candidates for surgery; Korlym tablets reducing cortisol is the key to improving cardiovascular abnormalities in people with mild Cushing's syndrome. It sells its products through specialty pharmacies and distributors. The company was founded in 1988 and is based in Menlo Park.
Lisa Su: Transforming AMD and Shaping the Semiconductor Industry
Explore Lisa Su's transformative leadership at AMD, including her role in revitalizing the company and her vision for semiconductor innovation.
26 Feb 2024
Klarna's Potential 2024 IPO: From Sequoia to Wall Street
Explore Klarna's journey from a 2005 startup to a fintech giant, its innovative business model, and the anticipation surrounding its 2024 IPO.
23 Feb 2024
Edward "Ted" Decker's Rise to the Top at Home Depot
Explore Ted Decker's transformative impact on Home Depot, including his leadership in retail innovation and strategic vision alongside Craig Menear.
15 Feb 2024
🇺🇸 United States